ArticleEuropean journal of applied physiology2026
Mediation analysis of metabolic and inflammatory markers in the association between physical activity and musculoskeletal disease: Findings from NHANES 2013-2018.
Article in European journal of applied physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biomarkers and Early Mechanisms of Sarcopenia: Central Roles of Mitochondrial Dysfunction, Inflammaging, Cellular Senescence, and Neuromuscular Degeneration.International journal of molecular sciences · 2026Review
- Correlation between preoperative nutritional status and postoperative clinical outcomes in patients undergoing artificial hip and knee replacement.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMusculoskeletal disease (MSD), including osteoarthritis, rheumatoid arthritis, osteoporosis, and sarcopenia, poses a serious social burden. While physical activity (PA) benefits musculoskeletal health, the optimal PA level for MSD prevention remains unclear. Clarifying risk factors and biological mechanisms is essential.
methodsThis study included 9,113 adults aged 20-60 years from NHANES 2013-2018. Blood and urine specimens were used to analyze metabolic and inflammatory markers. PA was assessed using the Global Physical Activity Questionnaire. Multivariate logistic regression, generalized additive models and mediation analysis were used to evaluate the relationships among PA, biomarkers and MSD.
resultsAmong 9113 participants, 2685 (29.5%) had MSD. PA levels of 600-1200 MET-min/week were associated with the greatest MSD risk reduction (24%; 95% CI 0.62-0.93) compared with inactivity after full adjustment. Participants with MSD showed higher levels of metabolic and inflammatory markers and lower PA levels (P < 0.05). Mediation analysis revealed that atherogenic index of plasma (AIP), triglycerides (TG), neutrophils (NEU), total cholesterol (TC), and triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) acted as complementary mediators at the highly active PA level only, with mediation proportions of 12.4%, 7.6%, 6.1%, 6.0%, and 5.7%. While, lymphocytes (LYM) served as an indirect-only mediator across both active and highly active PA levels, accounting for 21.8% of the total effect.
conclusionIn individuals aged 20-60 years, 600-1200 MET-min/week most effectively reduces MSD risk, with these associations likely mediated by metabolic and inflammatory markers. This study elucidates underlying biological mechanisms linking PA and MSD, highlighting potential metabolic and inflammatory pathways for prevention strategies.
Indexed as
Identifiers
40913129What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.